IRCT20200523047550N1
Completed
Phase 3
Evaluating effectiveness and safety of Umifenovir in the treatment (COVID-19)infection In patients referred to Tehran Imam Khomeini Hospital Complex
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Tehran University of Medical Sciences
- Enrollment
- 50
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients diagnosed with COVID\-19 infection based on PCR test for oropharyngeal and nasopharyngeal secretions or specific lung involvement in chest CT
- •Age over 18 years
- •The patient has PO tolerance
- •Gaining conscious satisfaction from the patient or first\-degree relatives responsible for the patient
- •No pregnancy and breastfeeding
Exclusion Criteria
- •Alt more than five times normal
- •Renal failure
- •History of any drug allergies
- •Pregnancy and lactation
- •Use of antiarrhythmic drugs
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
Evaluating the effects of Umifenovir (Arbidol) in COVID-19IRCT20151227025726N15Shahid Beheshti University of Medical Sciences100
Completed
Phase 3
mifenovir effectiveness in the treatment of COVID-19IRCT20200322046833N1Center for Progress and Development of Iran100
Recruiting
Phase 3
Investigating the efficacy and safety of Umifenovir in controlling the symptoms of patients with COVID-19IRCT20080901001165N46Center for Progress and Development of Iran200
Recruiting
Phase 3
Evaluation the effects of Favipiravir in COVID-19 patientsCOVID-19 pneumonia.COVID-19, virus identifiedU07.1IRCT20151227025726N14Shahid Beheshti University of Medical Sciences84
Recruiting
Phase 3
The effects of Favipiravir and Lopinavir/Ritonavir in treatment COVID-19IRCT20200506047323N3Bandare-abbas University of Medical Sciences60